# KymaThera

> Precision-medicine biotech developing mutant-selective PI3Kα inhibitors for cancer and vascular malformations.

## Why it is interesting

K-1728 targets a clinically validated pathway where efficacy has been constrained by hyperglycemia and incomplete mutation coverage. The $80 million Series B is intended to carry the wholly owned program into Phase 1 and through initial clinical proof-of-concept.

## Profile

- **Latest funding:** Series B — $80 million (October 6, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $80M
- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-10-08
- **Latest funding investors:** Alta Partners, Venrock, Foresite Capital, J. Wood Capital

## Key facts

- $80 million Series B announced as closed on October 6, 2026.
- More than $100 million raised since formation.
- Phase 1 patient dosing targeted for Q4 2026.

## Funding history

- Series B · $80 million · October 6, 2026
  Source: https://www.prnewswire.com/news-releases/kymathera-announces-80-million-series-b-financing-to-advance-k-1728-a-next-generation-pan-mutant-selective-pi3k-inhibitor-for-cancer-and-vascular-malformations-302899716.html

## Investors in our directory

- https://venturecapitaltracker.com/fund/alta-partners
- https://venturecapitaltracker.com/fund/venrock
- https://venturecapitaltracker.com/fund/foresite-capital

## Related articles

- https://venturecapitaltracker.com/2026-kymathera-80m-series-b-k1728-phase-1

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 8, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/kymathera